Abstract
The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.
Full Text
What is claimed is:
The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.
Timeline
Filed
02/25/2026Published
06/25/2026Granted
Not AvailableIPC Codes(43)
A61K 31/551:having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/05:Phenols
A61K 31/121:acyclic